Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Malignant Mesothelioma
About this trial
This is an interventional treatment trial for Malignant Mesothelioma focused on measuring localized malignant mesothelioma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven ipsilateral malignant pleural mesothelioma No contralateral thoracic or intra-abdominal involvement No distant metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 2,000/mm3 Platelet count greater than 100,000/mm3 No symptomatic anemia requiring transfusion Hepatic: Bilirubin less than 2.0 mg/dL No autoimmune hepatitis No history of decompensated liver disease; e.g. esophageal varices Ascites Albumin at least 2.5 mg/dL Increasing prothrombin time of at least 2.0 Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No symptomatic or debilitating cardiovascular disease, No concurrent thrombophlebitic or embolic disorders Pulmonary: No symptomatic or debilitating pulmonary disease, Pretreatment diffusion capacity greater than 30% of predicted normal Projected post-treatment FEV1 at least 1.0 L Other: No prior malignancy within 3 years, except nonmelanomatous skin cancer Carcinoma in situ of the cervix Ductal carcinoma in situ of the breast Not pregnant Fertile patients must use effective contraception No history of hypersensitivity to interferon or any component of the injection No uncontrolled diabetes (blood sugars consistently at least 300 mg/dL) No insulin dependent diabetes mellitus with history of ketoacidosis within 1 year No psychosis No uncontrolled thyroid abnormalities No active infection requiring intravenous antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: No prior debulking surgery No prior chest tube drainage with sclerosis if tumor resectable Prior thoracentesis allowed
Sites / Locations
- Office of S. Terry Kraus
- Fox Chase Cancer Center
- Virginia Oncology Associates